Please use this identifier to cite or link to this item:
|Title:||Targeted alpha therapy with 213Bi|
|Authors:||MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos|
|Citation:||Current Radiopharmaceuticals vol. 4 no. 4 p. 295 - 305|
|Publisher:||Bentham Science Publishers Ltd.|
|Type:||Articles in periodicals and books|
|Abstract:||The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.|
|JRC Institute:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.